mylotarg
(gemtuzumab ozogamicin)Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Usage: MYLOTARG is indicated for treating newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients aged 1 month and older, as well as for relapsed or refractory CD33-positive AML in patients aged 2 years and older.